Torii Pharmaceutical Co., Ltd. (TYO:4551)

Market Cap	126.19B
Revenue (ttm)	60.43B
Net Income (ttm)	5.04B
Shares Out	28.07M
EPS (ttm)	179.37
PE Ratio	25.06
Forward PE	n/a
Dividend	120.00 (2.73%)
Ex-Dividend Date	Dec 27, 2024

Volume	90,900
Average Volume	178,405
Open	4,450.00
Previous Close	4,450.00
Day's Range	4,355.00 - 4,480.00
52-Week Range	3,105.00 - 5,130.00
Beta	0.25
RSI	47.07
Earnings Date	Apr 25, 2025

About Torii Pharmaceutical

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents for renal diseases and hemodialysis, such as ENAROY tablets to treat anemia associated with CKD; Riona tablets for the treatment of hyperphosphatemia/iron deficiency anemia (IDA); and REMITCH, an oral therapeutic agent for the treatment of pruritus. The company provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus k...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1872
• Employees: 583
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4551

Financial Performance

In 2024, Torii Pharmaceutical's revenue was 60.43 billion, an increase of 10.59% compared to the previous year's 54.64 billion. Earnings were 5.04 billion, an increase of 22.41%.